PCSK9 Inhibition: From Current Advances to Evolving Future

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 19; p. 2972
• Main Authors: Liu, Chunping, Chen, Jing, Chen, Huiqi, Zhang, Tong, He, Dongyue, Luo, Qiyuan, Chi, Jiaxin, Hong, Zebin, Liao, Yizhong, Zhang, Shihui, Wu, Qizhe, Cen, Huan, Chen, Guangzhong, Li, Jinxin, Wang, Lei
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 23.09.2022; MDPI
• Subjects: Apolipoprotein E; Cardiovascular disease; Cardiovascular diseases; CD36 antigen; Cholesterol; clinical applications; Drug development; Forecasts and trends; Health aspects; Inflammation; Kexin; Lipoproteins; Lipoproteins (very low density); Liver; Low density lipoprotein; Low density lipoprotein receptors; Movement disorders; Neurodegenerative diseases; Nitric oxide; Pancreatic cancer; Parkinson's disease; PCSK9 inhibitors; Peptides; Proprotein convertases; Protease inhibitors; Proteins; R&D; Receptor density; Research & development; research status; Review; Scavenger receptors; security; Sepsis; Serine proteinase; Signal transduction; Statins; Subtilisin; Thrombosis; Toll-like receptors; China

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to reg...